Evidence map›Paper›PMID 32512806›Full record

ArticleJournal of clinical medicine2020

Erythropoietin, Fibroblast Growth Factor 23, and Death After Kidney Transplantation.

Michele F Eisenga, Maarten A De Jong, David E Leaf, Ilja M Nolte, Martin H De Borst, Stephan J L Bakker, Carlo A J M Gaillard

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03272854 (TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03272854 active not recruitingnot on this map

TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study

Typeobservational_patient_registrySponsorUniversity Medical Center GroningenRan2001 to 2031Enrolled606ConditionsDeath, Graft Failure, Death, Cardiac, DiabetesArmsNo intervention performed, the study is observational
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Michele F EisengaDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-2484-6233
Maarten A De JongDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
David E LeafDivision of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Ilja M NolteDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
Martin H De BorstDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-4127-8733
Stephan J L BakkerDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0003-3356-6791
Carlo A J M GaillardDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
University Medical Center Groningen · NLBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated levels of erythropoietin (EPO) are associated with an increased risk of death in renal transplant recipients (RTRs), but the underlying mechanisms remain unclear. Emerging data suggest that EPO stimulates production of the phosphaturic hormone fibroblast growth factor 23 (FGF23), another strong risk factor for death in RTRs. We hypothesized that the hitherto unexplained association between EPO levels and adverse outcomes may be attributable to increased levels of FGF23. We included 579 RTRs (age 51 ± 12 years, 55% males) from the TransplantLines Insulin Resistance and Inflammation Cohort study (NCT03272854). During a follow-up of 7.0 years, 121 RTRs died, of which 62 were due to cardiovascular cause. In multivariable Cox regression analysis, EPO was independently associated with all-cause (HR, 1.66; 95% CI 1.16-2.36;

Indexed as

deatherythropoietinfibroblast growth factor 23kidney transplantation

Identifiers

PMID32512806
PMCPMC7356141
OpenAlexW3034096997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.